Loading stock data…
OPRX
$6.70+0.47 (+7.54%)
Market ClosedLast close May 1
OptimizeRx Corporation operates as a digital healthcare technology company.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OptimizeRx Corporation in the Healthcare sector is trading at $6.70. The stock is currently near its 52-week low of $5.54, remaining 48.9% below its 200-day moving average. Technical signals show neutral RSI of 63 and bullish MACD crossover, explaining why OPRX maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.70
Potential Downside
34.6%
Whystock Fair Value$4.38
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$14.50+116.4%
Range$10.00 – $20.00
Fundamentals
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, wh...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$127.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.19
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.69%
Volume
Today's trading volume
471,046
Recent News
Smith Micro Software, Inc. (SMSI) Reports Q1 Loss, Tops Revenue Estimates
Smith Micro Software (SMSI) delivered earnings and revenue surprises of -100.00% and +0.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cadence Design Systems (CDNS) Q1 Earnings and Revenues Top Estimates
Cadence (CDNS) delivered earnings and revenue surprises of +4.26% and +1.69%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
OPRX edges past GDRX with AI-driven platform momentum, stronger estimates and lower valuation despite near-term revenue headwinds.
Pegasystems (PEGA) Misses Q1 Earnings and Revenue Estimates
Pegasystems (PEGA) delivered earnings and revenue surprises of -39.47% and -11.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Can OptimizeRx's Cash Strength Cushion Near-Term Headwinds?
OPRX's rising cash flow, DAAP adoption and expanding pharma ties boost outlook despite near-term revenue softness and cautious client spending.